fluorouracil has been researched along with Esophageal Diseases in 3 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Esophageal Diseases: Pathological processes in the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Capecitabine is a novel, orally administered fluoropyrimidine carbamate that has been approved for adjuvant treatment in patients with Stage III colon cancer, first-line metastatic colorectal cancer, and metastatic breast cancer, both as a single agent (for patients who are resistant to paclitaxel and anthracyclines) and in combination with docetaxel (after failure on anthracycline-based therapy)." | 2.43 | Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. ( Ajani, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Chen, EL | 1 |
| Weng, XR | 1 |
| Ajani, J | 1 |
| Cai, HY | 1 |
| Shu, YJ | 1 |
| Wang, GQ | 1 |
| Wu, AR | 1 |
| Lin, PZ | 1 |
| Liu, SF | 1 |
| Li, MX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Esophageal Diseases
| Article | Year |
|---|---|
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
2 other studies available for fluorouracil and Esophageal Diseases
| Article | Year |
|---|---|
[Analysis of the factors related to esophageal injuries in radiotherapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2011 |
[Therapy of severe epithelial dysplasia of esophagus. I. Therapeutic effects of Antitumor B III, Antitumor B and tilorone (author's transl)].
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Drug Combinations; Drugs, Chinese Herbal; Esophag | 1980 |